Key result
Treatment of adult humans with the MR antagonist spironolactone increases brown adipose tissue activity and thermogenesis, suggesting potential beneficial metabolic effects for obesity.
Why the study?
Does spironolactone increase brown adipose tissue activity and thermogenesis in adult humans?
Does spironolactone increase brown adipose tissue activity and thermogenesis in adult humans?
Spironolactone increases brown adipose tissue activity, suggesting a potential therapeutic approach for obesity and metabolic syndrome.
The recent article by Thuzar et al. (1) has shown for the first time that treatment of adult humans with the MR antagonist spironolactone (spiro) is capable of increasing brown adipose tissue (BAT) activity and thermogenesis, suggesting that MR antagonists (MRAs) may lead to beneficial metabolic effects and represent a valid approach to fight obesity and obesity-associated diseases (MetS). This article is protected by copyright. All rights reserved.
No takes yet. Share an insight, caveat, or question.
Armani et al. (2019) conducted a letter in Obesity and obesity-associated diseases (MetS). Spironolactone (MR antagonist) was evaluated on Brown adipose tissue (BAT) activity and thermogenesis. Treatment of adult humans with the MR antagonist spironolactone increases brown adipose tissue activity and thermogenesis, suggesting potential beneficial metabolic effects for obesity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: